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BMED 328 (ANTIMICROBIAL AGENTS)  SPRING SEMESTER, 2007 
 
INSTRUCTORS:  David Freeman, Office - SB 308, Phone: 243-4772, E-mail: david.freeman@umontana.edu  
            Office Hours:  Tuesday and Thursday, 11:00 - 1:00 p.m. and Friday, 1:10 - 4:00 p.m. 
        Jean Pfau, Office – SB 152C, Phone: 243-4529, E-mail: jean.pfau@umontana.edu
 
EXAMS AND GRADING: 
  First Exam:  Wednesday, FEB. 14 . . . . . . 60 points 
  Second Exam: Friday, MAR. 23 . . . . . . 80 points 
  Third Exam:  Friday, APRIL 27  . . . . . . 80 points 
  Final Exam:  Monday, MAY 7          . . . . . 100 points  
  10 Point Quizzes:   Best 5 or 6 out of 6 scores. .  50 or 60 points  
  Total Points: 370 or 380   A>92%  A->90%  B+>88%  B>82%  B->80%  C+>78%  C>72%  C->70%  D>65%  
1. All EXAMS are comprehensive 
2. All exams and quizzes must be taken at scheduled times 
3. Instructor must be informed BEFORE missing a scheduled exam period for GOOD REASONS 
4. Missed exam periods must be made up within 2 days 
5. Corrections to exams or quizzes must be requested within 7 days after returning 
 
STUDENT PERFORMANCE OBJECTIVES:  
   1) Know the normal relevant biochemical pathways and the major biochemical mechanisms 
     of action for the different classes of drugs 
   2) Know the biochemical mechanisms involved in the development of resistance to different 
    classes of antimicrobial agents 
   3) Given a representative chemical structure or name of a drug, know its biochemical mechanisms 
of action and for development of resistance  
   4) Given a representative chemical structure or name of a drug, know its major chemical, 
pharmacologic, or therapeutic categorization 
   5) Given a representative chemical structure or name of a drug, know its major 
therapeutic uses and spectrum of activity 
   6) Given a representative chemical structure or name of a drug, know important aspects of its 
absorption, pharmacokinetics, and metabolism 
   7) Know important chemical features (i.e., polar or lipophilic properties, labile groups, etc.) that 
affect the absorption, distribution, metabolism, elimination, potency, stability, or formulation 
of a class of antimicrobial agents 
   8) Given the chemical structure of an antimicrobial agent, know important chemical changes 
that will predictably alter its properties (i.e., potency, duration of action, stability, etc.) 
   9) Given a representative chemical structure or name of a drug, know its most common or serious 
adverse or side effects  
 
REQUIRED TEXT:  Goodman & Gilman, "The Pharmacological Basis of Therapeutics", 11TH  Edition 
 
 Reading                                                        
  in Text 
 
1095-1109 I. General Considerations, Categorization, and 
   Sensitivity Testing of Antimicrobial Agents 
 
The following areas will be covered for each outline topic below: 
1. General Chemical Structures and Properties of Agents 
2. Biochemical Mechanisms of Action for Agents 
3. Biochemical Mechanisms Involved in the Development of Microbial Resistance 
4. Important Aspects of Absorption, Distribution, Metabolism, and Elimination for Agents 
5. Antimicrobial Spectrum of Activity for Agents 




  II.  Antibacterial Agents 
1111-1118  A.  Sulfonamides and TRIMETHOPRIM 
1119-1122  B.  Quinolones, Fluoroquinolones 
1122-1124  C.  METHENAMINE and NITROFURANTOIN 
   D.  Beta-lactam Antibiotics 
1127-1143         1. Penicillins 
1151-1152         2. Beta-lactamase inhibitors (CLAVULANIC ACID, SULBACTAM, TAZOBACTAM) 
1143-1150         3. Cephalosporins 
1150-1151         4. Carbapenems (IMIPENEM, MEROPENEM, ERTAPENEM) 
1151          5.  Monobactams (AZTREONAM)  
1193-1199  E.  VANCOMYCIN, TEICHOPLANIN, DAPTOMYCIN,  
    POLYMYXIN, BACITRACIN, MUPIROCIN 
1155-1168, 1193 F.  Aminoglycosides, SPECTINOMYCIN 
1173-1179  G.  Tetracyclines, Glycylcyclines (TIGECYCLINE) 
1182-1187  H.   Macrolides (ERYTHROMYCIN, AZITHROMYCIN, CLARITHROMYCIN) 
1187-1188  I.   Ketolides (TELITHROMYCIN) 
1179-1182  J.  CHLORAMPHENICOL 
1188-1190  K.   CLINDAMYCIN 
1190-1191  L.  Streptogramins (QUINUPRISTIN, DALFOPRISTIN) 
1192-1193  M.  Oxazolidinones (LINEZOLID) 
1057-1060  N.  METRONIDAZOLE 
 
  III.  Anti-mycobacterial Agents 
1203-1214  A. Drugs for Tuberculosis  (ISONIAZID, RIFAMPIN, PYRAZINAMIDE, ETHAMBUTOL) 
1216-1218  B. Drugs for Mycobacterium Avium Complex Infections 
 
  IV.  Antifungal Agents 
1225-1230  A. AMPHOTERICIN B and FLUCYTOSINE 
1230-1234  B. Azole Antifungals - Imidazoles and Triazoles (KETOCONAZOLE, FLUCONAZOLE,  
    ITRACONAZOLE, VORICONAZOLE, POSACONAZOLE) 
1235   C. Echinocandins (CASPOFUNGIN, MICAFUNGIN, ANIDULAFUNGIN) 
1235-1240  D. Miscellaneous and Topical Antifungal Agents  (GRISEOFULVIN, TERBINAFINE,  
      CLOTRIMAZOLE, MICONAZOLE, TOLNAFTATE, NYSTATIN, UNDECYLENIC ACID) 
 
  V.  Antiviral Agents 
1243-1245  A. Overview of Viral DNA and RNA Biochemical Processes 
1247-1248  B. Overview of Biochemical Mechanisms of Action and Resistance Development 
1246-1256  C. Non-HIV Antiviral Agents  (ACYCLOVIR, VALACYCLOVIR, CIDOFOVIR,   
    DOCOSANOL, FAMCICLOVIR, PENCICLOVIR, FOMIVIRSEN, FOSCARNET, 
    GANCICLOVIR, VALGANCICLOVIR, TRIFLURIDINE, VIDARABINE) 
1256-1260  D. Antiinfluenza Agents (AMANTADINE, RIMANTIDINE, OSELTAMIVIR, ZANAMIVIR) 
1260-1268  E. Antihepatitis Agents, Other Antiviral Agents, and New Strategies 
 
VI. HIV Antiviral Agents 
1273-1275  A. Overview of HIV Infection  
1276-1280  B. History and Principles of HIV Chemotherapy 
1280-1292  C. Nucleoside Reverse Transcriptase Inhibitors    (ABACAVIR, DIDANOSINE, 
    EMTRICITABINE, LAMIVUDINE, STAVUDINE, TENOFOVIR, 
    ZALCITABINE, ZIDOVUDINE)  
1292-1297  D. Nonnucleoside Reverse Transcriptase Inhibitors 
    (DELAVIRDINE, EFAVIRENZ, NEVIRAPINE) 
1297-1308  E. HIV Protease Inhibitors  (AMPRENAVIR, ATAZANAVIR, DARUNAVIR,   
    FOSAMPRENAVIR, INDINAVIR, LOPINAVIR, NELFINAVIR, RITONAVIR, 
    SAQUINAVIR, TIPRANAVIR) 
1308-1310  F. Entry Inhibitors (ENFUVIRTIDE) and New Drugs in Development 
